Clara Alsinet

Author PubWeight™ 31.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 4.35
2 Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 4.03
3 Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011 2.66
4 Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009 2.42
5 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 2.42
6 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
7 Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012 1.71
8 IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010 1.66
9 New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010 1.46
10 Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012 1.44
11 Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012 1.26
12 Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 2012 1.02
13 Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 2010 1.01
14 VEGF signaling in cancer treatment. Curr Pharm Des 2014 0.91
15 Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 2012 0.88
16 Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 2011 0.84
17 One patient, two lesions, two oncogenic drivers of gastric cancer. Genome Biol 2014 0.75
18 microRNAs and the MYC network: a major piece in the puzzle of liver cancer. Gastroenterology 2011 0.75
19 Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies? J Hepatol 2013 0.75
20 Genetically engineered mouse models: future tools to predict clinical trial results in oncology? Future Oncol 2013 0.75